FDA issues mergency use authorization for COVID-19 antigen diagnostic test


Washington, Jul 7 (IANS): The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for a COVID-19 antigen diagnostic test, the Becton Dickinson Veritor System for Rapid Detection of SARS-CoV-2.

This is the second antigen test the FDA has authorized for the detection of SARS-CoV-2 antigens, reports Xinhua news agency.

This test is authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 for high, moderate, or waived complexity testing, according to the FDA.

"Expanding America's testing capabilities is the result of partnership and ingenuity between the federal government, private sector and academia," FDA Commissioner Stephen Hahn said on Monday.

Antigen tests play an important role in the overall response against COVID-19, including as a point-of-care test that can potentially scale up to test millions of Americans quickly, he added.

In May, the FDA approved EUA to American company Quidel Corp for the first COVID-19 antigen test.

  

Top Stories


Leave a Comment

Title: FDA issues mergency use authorization for COVID-19 antigen diagnostic test



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.